-
In early March, the National Medical Products Administration approved Jaypirca® (pirtobrutinib) for the treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have received at least one prior systemic therapy, including a Bruton’s tyrosin...Read more »
-
Exciting news has recently emerged from the Center for Drug Evaluation (CDE) of China’s National Medical Products Administration: the clinical trial for KSD-101 Injection, developed by Hensen Bio, has been approved. The indicated use is for “EBV-associated hematological tumors that ha...Read more »
-
Recently, the China National Medical Products Administration (NMPA) approved a new indication for Bireociclib, a Class 1 innovative drug independently developed by Xuanzhu Biopharmaceutical. The new indication is for use in combination with an aromatase inhibitor as an initial endocrine therapy f...Read more »
-
On February 28, 2026, the National Medical Products Administration (NMPA) officially approved the marketing of JMKX001899 sulfate for the treatment of adult patients with KRAS G12C-mutated advanced non-small cell lung cancer (NSCLC) who have received at least one prior systemic therapy. JMKX00189...Read more »
-
On February 13, 2026, the Center for Drug Evaluation (CDE) of China’s National Medical Products Administration announced that GFH375 tablets have been included in the Breakthrough Therapy Designation for the treatment of patients with KRAS G12D-mutant non-small cell lung cancer (NSCLC) who ...Read more »
-
On February 12, 2026, the Center for Drug Evaluation (CDE) of China’s National Medical Products Administration announced on February 4 that ENHERTU® (trastuzumab deruxtecan) has been proposed for inclusion in the Breakthrough Therapy Program for use as adjuvant therapy in adult patients with HER2...Read more »
-
Beijing South Region Oncology Hospital International Department is proud to offer international patients access to cutting-edge cancer therapies, including Boron Neutron Capture Therapy (BNCT) – a revolutionary treatment that has already changed lives. A Real-Life Proof: Mrs. Wu’s Journey In 2022...Read more »
-
On February 9, 2026, the official website of the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) announced that ZL-1310 for injection, a novel DLL3-targeting antibody-drug conjugate (ADC), is planned to be granted Breakthrough Therapy Designation. As a mem...Read more »
-
For every patient who travels a long distance to seek our care, we deeply understand: what you bring is not only complex medical records but also the trust and hopes of your entire family. At the Beijing South Region Oncology Hospital International Department, we witness such stories every day—ho...Read more »
-
Facing the treatment challenge of HER2-positive colorectal cancer, we fully understand your urgent desire for more effective and advanced treatment options. Today, we bring major encouraging news from China’s oncology field. **Breakthrough Therapy Is Within Reach: SHR-A1811 Demonstrates Exception...Read more »
-
Recently, China’s National Medical Products Administration officially approved the combination therapy of Anlotinib Hydrochloride and Penpulimab by Chia Tai Tianqing for the first-line treatment of advanced hepatocellular carcinoma. This marks the tenth approved indication for Anlotinib Hyd...Read more »
-
Recently, the field of cancer treatment in China has achieved a significant milestone. On January 7, 2025, the National Medical Products Administration officially approved the innovative drug SHR-1701 for market use. It is indicated in combination with chemotherapy as a first-line treatment for l...Read more »
Cooperative medical institution of
Beijing Cancer Hospital